// App-Quantinova.ai

e15126 : Dynamic angiogenic switch as predictor of response to chemotherapy+ bevacizumab in patients with metastatic colorectal cancer.

Researchers

Presenter

  • Antonio Cubillo

Principal Investigators

  • Rafael Alvarez-Gallego

  • Manuel Munoz

  • Gregory Russell Pond

  • Gema Sanchez

  • Maria Martin

  • Jesus Rodriguez-Pascual

  • Elena Garralda

  • Estela Vega

  • Rodrigo Toledo

  • Emilio De Vicente

  • Yolanda Quijano

  • Cesar Munoz

  • Lisardo Ugidos

  • Manuel Hidalgo

  • Sofia Perea

Medical Centers

  • Centro Integral Oncologico Clara Campal- Hospital Madrid Norte Sanchinarro, Madrid, Spain

  • Centro Nacional de Investigaciones Oncologicas, Madrid, Spain

  • Ontario Clinical Oncology Group, Hamilton, ON, Canada

  • Centro Nacional de Investigaciones Oncologicas, Madrid, Spain

  • Centro Intengral Oncologico Clara campal, Madrid, Spain

  • START Department, Centro Integral Oncologico Clara Campal, Madrid, Spain

  • START Department, Centro Integral Oncologico Clara Campal, Madrid, Spain

  • Centro Nacional de Investigaciones Oncologicas, Madrid, Spain

Locations

  • Spain

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • Phosphatidylinositol Glycan, Class F

  • Hepatocyte growth factor

  • Interleukin 18

  • Matrix metallopeptidase 9

Drug/Treatment

  • Capecitabine

  • Bevacizumab

  • Oxaliplatin

  • Irinotecan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02075086

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved